Public market investors (Hong Kong public tranche and international offering) Investment Insilico Medicine | Undisclosed Deal

← Back to Deal Tracker

↗InvestmentVerified

Public market investors (Hong Kong public tranche and international offering)

→↓

Insilico Medicine

Deal Value

Undisclosed

Announced

Wednesday, December 31, 2025

Deal Details

Insilico Medicine raised roughly HK$2.28 billion (over US$290 million) in a heavily oversubscribed Hong Kong IPO, the largest biotech flotation in the city in 2025.

A financial investment providing capital in exchange for equity or strategic partnership.

Related News

Insilico Medicine debuts on HKEX in record AI biotech IPO

AI‑driven drug discovery firm Insilico Medicine listed on the Hong Kong Stock Exchange under code 03696.HK, raising about HK$2.28 billion in what is described as Hong Kong’s largest biotech IPO of 2025. The shares were priced at HK$24.05 and opened around HK$35, valuing the company at roughly HK$19.5 billion.([prnewswire.com](https://www.prnewswire.com/news-releases/qiming-venture-partners-insilico-medicine-successfully-lists-on-hong-kong-stock-exchange-302650996.html?utm_source=openai))

Dec 31, 2025

View Original Source↗

More Investment Deals Public market investors (Hong Kong public tranche and international offering) Deals Insilico Medicine Deals